Symbiosis Honoured with Prestigious King’s Award for Enterprise for International Trade

Stirling, UK – 7th May 2025 – Symbiosis Pharmaceutical Services (Symbiosis), a global biopharmaceutical Contract Manufacturing Organisation (CMO) specialising in the sterile fill finish of injectable drug products has been awarded a 2025 King’s Award for Enterprise in the International Trade category, the UK’s highest official accolade for British businesses.

This prestigious recognition celebrates Symbiosis’ outstanding success in international markets, underlining its role as a trusted global partner in the manufacture of life-saving therapies. With clients across North America, Europe and the Asia-Pacific region, Symbiosis has experienced sustained growth, driven by its strategic focus of serving the global biotechnology and pharmaceutical industries.

The King’s Awards for Enterprise are granted annually by His Majesty King Charles III and are regarded as the pinnacle of British business achievement. Symbiosis joins an exclusive group of only 197 UK organisations to receive the recognition in 2025, gaining the right to display the King’s Award emblem for the next five years, symbolising excellence and credibility on the world stage.

“We are greatly honoured to receive the Kings Award for Enterprise” said Colin MacKay, CEO of Symbiosis. This achievement reflects the incredible dedication and expertise of the whole Symbiosis team, and the trust placed in us by our international clients to help bring their life-changing medicines to patients around the world. It’s a proud moment for our company and for both the UK and Scottish life sciences sector”.

This award not only acknowledges Symbiosis’ commercial performance overseas, but also its ongoing contribution to the UK’s global reputation for manufacturing excellence, and quality in the life sciences sector.

As Symbiosis looks ahead, the company remains committed to expanding its service offering and its global reach by supporting biotechnology and pharmaceutical clients in the manufacture and supply of complex injectable medicines that improve and save lives.

The King’s Award, previously known as The Queen’s Award for Enterprise, was renamed in 2023 to continue Queen Elizabeth II’s legacy of celebrating excellence in the UK business community.

ENDS

About Symbiosis Pharmaceutical Services:

Symbiosis Pharmaceutical Services (Symbiosis) is a world-class Contract Manufacturing Organisation (CMO) located in Stirling, UK, and is a specialist sterile GMP manufacturer of biopharmaceuticals for use in clinical trials and commercial sales globally. Symbiosis is MHRA-licensed and FDA-inspected and offers a range of services including the aseptic fill/finish of medicines into vials, analytical testing, QP release of product, inspection, labelling, packaging and GMP temperature-controlled storage and shipment of medicines.

The Symbiosis facility in Stirling, Scotland, was designed for biologic and small molecule pharmaceutical production to support biotechnology and pharmaceutical companies worldwide requiring sterile injectable pharmaceutical products manufactured in short timeframes for clinical trial use and commercial supply.

Regulatory compliance, technical capability and operational flexibility are core to the Symbiosis value proposition along with direct access to a highly experienced team of life science experts. By adding value directly to the new drug development projects and the commercial manufacturing supply chain requirements of its clients, Symbiosis has demonstrated consistent annual growth and built long-term relationships with its client base globally.

For more information on Symbiosis visit http://www.symbiosis-pharma.com or follow us on LinkedIn.

Media Contact:
Rachael Heath
ramarketing
rachael@ramarketingpr.com
www.ramarketingpr.com